Spots Global Cancer Trial Database for campath
Every month we try and update this database with for campath cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease | NCT00129753 | Hodgkin's Disea... Lymphoma | Alemtuzumab (Ca... | 18 Years - | M.D. Anderson Cancer Center | |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | NCT00047060 | Mycosis Fungoid... Sezary Syndrome | A matched perip... cyclosporine fludarabine Campath | 18 Years - 70 Years | National Institutes of Health Clinical Center (CC) | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Campath Maintenance in Chronic Lymphocytic Leukemia | NCT00587847 | Chronic Lymphoc... | Campath | 18 Years - | Northwell Health | |
| Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | NCT00328198 | B-Cell Chronic ... | Alemtuzumab Alemtuzumab | 18 Years - | Sanofi | |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center | |
| Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | NCT00046683 | B Cell Chronic ... | alemtuzumab | 18 Years - | Sanofi | |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene | NCT01875237 | Leukemia Myeloma Myeloproliferat... | Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire | 18 Years - 65 Years | M.D. Anderson Cancer Center | |
| Alemtuzumab and CHOP in T-cell Lymphoma | NCT00646854 | Lymphoma, T-Cel... | CHOP14 chemothe... CHOP14 chemothe... | 18 Years - 60 Years | University of Aarhus | |
| Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | NCT00505921 | Lymphoma | Campath-1H G-CSF GM-CSF BCNU Stem Cell Trans... Preparative Reg... Cytarabine Etoposide Melphalan Campath Fludarabine Cyclophosphamid... Low dose total ... | - 70 Years | M.D. Anderson Cancer Center | |
| Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies | NCT00943592 | Advanced Hemato... Leukemia Preleukemia | Clofarabine Melphalan Campath Stem Cell Trans... | 18 Years - 75 Years | University of Chicago | |
| Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | NCT00077961 | Non-Hodgkin's L... | CAMPATH (alemtu... | 18 Years - | Sanofi | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | NCT00051701 | Non-Hodgkins Ly... | alemtuzumab | 18 Years - | Sanofi | |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies | NCT00943293 | Preleukemia Myeloproliferat... Lymphoma Myeloma Graft Versus Ho... | Fludarabine Melphalan Campath | 18 Years - | University of Chicago | |
| Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | NCT01030900 | Hodgkin Lymphom... Diffuse Large B... | Campath Rituximab EPOCH | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | NCT00051701 | Non-Hodgkins Ly... | alemtuzumab | 18 Years - | Sanofi | |
| Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML | NCT00416884 | Leukemia | Campath Fludarabine Total Body Irra... T-Cell Deplete | 4 Years - 75 Years | OHSU Knight Cancer Institute | |
| Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | NCT00579111 | Myelodysplastic... Acute Myelogeno... Acute Lymphobla... Chronic Myeloge... Multiple Myelom... Plasma Cell Dys... Lymphoprolifera... Hematologic Dis... | Campath Busulfan Fludarabine Hematopoietic s... FK-506 | - 70 Years | Baylor College of Medicine | |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy | NCT00800943 | B-Cell Chronic ... | Alemtuzumab (Ca... | 18 Years - | Chronic Lymphocytic Leukemia Research Consortium | |
| Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | NCT00077961 | Non-Hodgkin's L... | CAMPATH (alemtu... | 18 Years - | Sanofi | |
| Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies | NCT00943319 | Leukemia Lymphoma Myeloma | Busulfan Fludarabine Campath Stem Cell Trans... | 18 Years - | University of Chicago | |
| Safety and Efficacy of Campath in Nonmyeloablative Transplantation | NCT00038844 | Lymphoma Leukemia | Campath-1 H (Al... Fludarabine Cyclophosphamid... Rituximab | - 70 Years | M.D. Anderson Cancer Center | |
| Non-Myeloablative Allogeneic Stem Cell Transplantation | NCT00525876 | Lymphoma | Cyclophosphamid... Fludarabine Rituximab Alemtuzumab Allogeneic Stem... | - 70 Years | M.D. Anderson Cancer Center | |
| Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia | NCT00462332 | Leukemia | Fludarabine Campath Transplant Campath Fludarabine Campath Campath | - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | NCT00330252 | Chronic Lymphoc... | Rituximab Alemtuzumab | 18 Years - | Dana-Farber Cancer Institute | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapy | NCT00800943 | B-Cell Chronic ... | Alemtuzumab (Ca... | 18 Years - | Chronic Lymphocytic Leukemia Research Consortium | |
| T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00683046 | Acute Myelogeno... Lymphoid Leukem... Chronic Myeloge... Malignant Lymph... Hodgkin's Disea... Chronic Lymphoc... Myeloproliferat... Anemia, Aplasti... Myelodysplastic... | Fludarabine Melphalan Stem cells Campath | - 100 Years | University of Chicago | |
| Alemtuzumab + Rituximab Consolidation in CLL | NCT00771602 | Chronic Lymphoc... Leukemia | Rituximab Alemtuzumab | 18 Years - | M.D. Anderson Cancer Center | |
| Stem Cell Transplant for Hematologic Diseases | NCT00058825 | Hematologic Mal... | Campath 1H Fludarabine Stem Cell Trans... Total Body Irra... FK506 (Tacrolim... | - 70 Years | Baylor College of Medicine | |
| Stem Cell Transplant for Hematologic Diseases | NCT00058825 | Hematologic Mal... | Campath 1H Fludarabine Stem Cell Trans... Total Body Irra... FK506 (Tacrolim... | - 70 Years | Baylor College of Medicine | |
| Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia | NCT00046683 | B Cell Chronic ... | alemtuzumab | 18 Years - | Sanofi | |
| Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | NCT01082939 | Chronic Lymphoc... | Fludarabine Cyclophosphamid... Alemtuzumab Rituximab | - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
